Results 71 to 80 of about 3,407,318 (341)
Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?
The association between coagulation and cancer development has been observed for centuries. However, the connection between inflammation and malignancy is also well-recognized. The plethora of evidence indicates that among multiple hemostasis components,
M. Wojtukiewicz +4 more
semanticscholar +1 more source
Introduction Rheumatoid sarcopenia, characterized by the progressive loss of skeletal muscle mass and function, is a frequent comorbidity in rheumatoid arthritis (RA), linked to prolonged, severe systemic inflammation. Purinergic signaling (adenosine, AMP, and ATP) plays a crucial role in inflammation, myogenesis, and muscle hypertrophy.
Miguel Marco‐Bonilla +13 more
wiley +1 more source
Delayed retropharyngeal hematoma following a minor facial blunt trauma
We described the case of 75 years old male patient with an airway obstruction due to retropharyngeal hematoma that developed after a minor blunt trauma to the face. The patient was not taking any anticoagulants or antiplatelet agents and did not have any
Yuya Kitai, Ryota Sato
doaj +1 more source
Portal vein thrombosis after laparoscopic splenectomy: an ongoing clinical challenge. [PDF]
ObjectivesPortal vein thrombosis (PVT) following open splenectomy is a potentially lethal complication with an incidence of up to 6%. The objective of this report is to describe our management of a recent laparoscopic case, discuss current therapies, and
Kee, Stephen T +4 more
core +2 more sources
Objectives Polymyalgia rheumatica (PMR) is a common indication for long‐term glucocorticoid (GC) treatment. Bone‐ and gastro‐protective medications are recommended for those at high‐risk of adverse events from GCs but no trials have evaluated their effectiveness in PMR.
Helen Twohig +5 more
wiley +1 more source
The SAFEST Study: Survey on Antiplatelets in Flow Diversion for Aneurysm Endovascular Treatment
Background Flow diversion has emerged as a promising treatment strategy for intracranial aneurysms, yet the influence of antiplatelet therapy on treatment outcomes remains uncertain. Regional and institutional variability in antiplatelet regimens further
Sophia Hohenstatt +10 more
doaj +1 more source
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial [PDF]
Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage.
Al-Shahi Salman, Rustam +16 more
core +1 more source
Aim Our international cohort study assessed the comparative effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) among patients with non‐valvular atrial fibrillation (NVAF) using antiarrhythmic drugs. Methods Using the United Kingdom's (UK's) Clinical Practice Research Datalink Aurum and Québec claims data, we
Fabian Maximilian Meinert +5 more
wiley +1 more source
Xin Liu,1 Xiaoning He,1 Jing Wu,1 Da Luo1,2 1School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, People’s Republic of China; 2Tianjin Health Development Research Center, Tianjin, People’s Republic of ...
Liu X, He X, Wu J, Luo D
doaj
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]
We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo +41 more
core +5 more sources

